Get started
Award

PrEP and ART adherence monitoring using dried blood spots

Description: PUBLIC HEALTH RELEVANCE: Inadequate adherence to HIV pre-exposure chemoprophylaxis (PrEP) and antiretroviral therapy (ART) is common, and the leading cause of therapeutic failure. Better ways are needed to measure adherence in patients. This application will validate a new way to monitor adherence to tenofovir-based PrEP and ART using a long-lasting metabolite of tenofovir, called tenofovir-diphosphate in dried blood spots. We believe that this new measure can diagnose adherence problems preemptively, allowing for proactive interventions to improve patient outcomes.
Funding type: cooperative_agreement
Funder scheme: U01
Start date: 2013-04-15
End date: 2017-03-31
Investigator: PETER L. ANDERSON
Institution: UNIVERSITY OF COLORADO DENVER
Field: Medicine
Funded outputs count: 25
Funder award ID: U01AI106499
OpenAlex ID: G2102942554
An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics
2026 · Peter L. Anderson, Alina PS Pang, et al. · medRxiv · 4
Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum
2025 · Yifan Yu, Kristina M. Brooks, et al. · Clinical Pharmacokinetics
PDF
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate
2021 · Jenna L. Yager, Kristina M. Brooks, et al. · AIDS · 34
Letter to the Editor: Revisiting the Pharmacological Forgiveness of HIV Pre-Exposure Prophylaxis
2021 · Mustafa E. Ibrahim, David V. Glidden, et al. · AIDS Research and Human Retroviruses · 1
Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis
2020 · Mustafa E. Ibrahim, Jose R. Castillo-Mancilla, et al. · AIDS Research and Human Retroviruses · 19
HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health
2019 · Simon B. Ascher, Rebecca Scherzer, et al. · AIDS · 20
Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors
2019 · Holly Janes, Marshall D. Brown, et al. · PLoS ONE · 3
PDF
Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project
2019 · Matthew A. Spinelli, David V. Glidden, et al. · AIDS Research and Human Retroviruses · 12
Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing
2019 · Matthew A. Spinelli, David V. Glidden, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 22
Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine
2018 · Catherine A. Koss, Albert Y. Liu, et al. · AIDS · 14
Skating on thin ice: stimulant use and sub‐optimal adherence to HIV pre‐exposure prophylaxis
2018 · J Carlo Hojilla, David Vlahov, et al. · Journal of the International AIDS Society · 66
PDF
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine
2018 · David V Glidden, Kathleen Mulligan, et al. · Clinical Infectious Diseases · 76
PDF
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy
2017 · Peter L. Anderson, Albert Y. Liu, et al. · Antimicrobial Agents and Chemotherapy · 274
PDF
Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis
2017 · David V. Glidden, Kathleen Mulligan, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 33
Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates
2016 · Xinhui Chen, Sharon M. Seifert, et al. · PLoS ONE · 15
PDF
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing
2016 · Jose Castillo-Mancilla, Sharon Seifert, et al. · Antimicrobial Agents and Chemotherapy · 70
Development and validation of an LC–MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate
2016 · Xinhui Chen, Kevin J. McAllister, et al. · Biomedical Chromatography · 6
Pharmacology supports on-demand PrEP
2016 · David V Glidden, Peter L Anderson, et al. · The Lancet HIV · 17
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women
2016 · Peter L. Anderson, Daniel Reirden, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 19
Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine
2016 · Xinhui Chen, Jose R. Castillo-Mancilla, et al. · Antimicrobial Agents and Chemotherapy · 11
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots
2016 · Jia-Hua Zheng, Caitlin Rower, et al. · Journal of Pharmaceutical and Biomedical Analysis · 134
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension
2016 · David V. Glidden, K. Rivet Amico, et al. · Clinical Infectious Diseases · 59
PDF
Nondaily preexposure prophylaxis for HIV prevention
2015 · Peter L. Anderson, J. Gerardo García-Lerma, et al. · Current Opinion in HIV and AIDS · 37
Accuracy of Electronic Medical Record Medication Reconciliation in Emergency Department Patients
2015 · Andrew A. Monte, Peter Anderson, et al. · Journal of Emergency Medicine · 46
Defining success with HIV pre-exposure prophylaxis
2015 · Jessica E. Haberer, David R. Bangsberg, et al. · AIDS · 320
Year
Topic